Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics

AIMS: The aims of the present study were to evaluate the risk of cardiac failure (CF) associated with 15 anticancer protein kinase inhibitors (PKIs) through a case/noncase analysis and to identify which PK(s) and pathways are involved in PKI‐induced CF. METHODS: In order to evaluate the risk of CF,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Clin Pharmacol
Egile Nagusiak: Patras de Campaigno, Emilie, Bondon‐Guitton, Emmanuelle, Laurent, Guy, Montastruc, Francois, Montastruc, Jean‐Louis, Lapeyre‐Mestre, Maryse, Despas, Fabien
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Drug Safety
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465347/
https://ncbi.nlm.nih.gov/pubmed/28098949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13238
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak